Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Keeps Avandia On The Market But Looks To RECORD For More Clarity On CV Risk

This article was originally published in The Pink Sheet Daily

Executive Summary

Rosiglitazone will be available under a Risk Evaluation and Mitigation Strategy with restricted distribution pending an independent panel's re-adjudication of CV endpoints in the much-maligned, open-label RECORD study.

You may also be interested in...



CEO Witty's 2017 Exit Could Hasten Glaxo's Consumer Business Decision

Glaxo CEO Andrew Witty will retire from the company in 2017 after nine years at the helm, opening the door to the possibility of broader change. His biggest legacy could be the multi-asset swap he orchestrated with Novartis in 2014 that created a consumer health care JV with the Swiss firm.

Witty Exiting GSK In 2017, Raising Questions About The Firm’s Future

GlaxoSmithKline CEO Andrew Witty will retire from the company in 2017 after nine years at the helm, opening the door to the possibility of broader change.

Witty Exiting GSK In 2017, Raising Questions About The Firm’s Future

GlaxoSmithKline CEO Andrew Witty will retire from the company in 2017 after nine years at the helm, opening the door to the possibility of broader change.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS071221

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel